Company Description
Carmell Corporation operates as a bio-aesthetics company.
The company utilizes Carmell Secretome to support skin and hair health. Its Carmell Secretome consists of growth factors and proteins extracted from allogeneic human platelets sourced from tissue banks.
The company also developed a microemulsion formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products.
In addition, the company is also developing a line of men's products and a line of topical haircare products.
It has licensing agreement with Carnegie Mellon University to develop and commercialize biocompatible plasma-based plastics.
The company was formerly known as Carmell Therapeutics Corporation and changed its name to Carmell Corporation in November 2023.
Carmell Therapeutics Corporation was founded in 2008 and is headquartered in Pittsburgh, Pennsylvania.
| Country | United States |
| Founded | 2007 |
| Industry | Household & Personal Products |
| Sector | Consumer Staples |
| Employees | 9 |
| CEO | Rajiv Sarman Shukla |
Contact Details
Address: 2403 Sidney Street, Suite 300 Pittsburgh, Pennsylvania 15203 United States | |
| Phone | 412-894-8248 |
| Website | carmellrx.com |
Stock Details
| Ticker Symbol | CTCX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001842939 |
| CUSIP Number | 142922103 |
| ISIN Number | US1429221039 |
| Employer ID | 86-1645738 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Rajiv Sarman Shukla | Executive Chairman and Chief Executive Officer |
| Dr. Phil Campbell Ph.D. | Founder and Chief Scientific Officer |
| Dr. Lee Weiss Ph.D. | Founder |
| Dr. James Burgess M.D. | Founder |
| Bryan J. Cassaday | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 14, 2024 | ARS | Filing |
| Jun 14, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Jun 14, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 5, 2024 | 424B3 | Prospectus |
| Jun 3, 2024 | EFFECT | Notice of Effectiveness |
| May 30, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 17, 2024 | UPLOAD | Filing |
| May 15, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Apr 30, 2024 | D | Notice of Exempt Offering of Securities |